Life Sciences Pioneer Todd Dickinson, Ph.D., Appointed as CEO; Spatial Biology Innovator Ye Fu, PhD., Appointed as CTO

生命科学先驱托德·迪金森博士，被任命为首席执行官；空间生物学创新者叶福博士。，任命为首席技术官

BOSTON, Nov. 2, 2023 /PRNewswire/ -- Stellaromics, a leading provider of in situ spatial multi-omics technology, today announced that the company has raised $25 million in a Series A financing round. The Series A financing round included Plaisance Capital Management and a private family office based in Silicon Valley.

波士顿，2023年11月2日/PRNewswire/-Stellaromics，原位空间多组学技术的领先提供商，今天宣布该公司在a系列融资回合中筹集了2500万美元。A系列融资包括Plaisance资本管理和位于山谷的私人家庭办公室。

Founded in 2022, the company is developing next-generation spatial technology that promises to accelerate the development of fundamentally novel drug treatments, including for autoimmune diseases, cancer, neuropsychiatric disorders, and infectious diseases..

该公司成立于2022年，正在开发下一代空间技术，有望加速基本上新型药物治疗的开发，包括自身免疫性疾病，癌症，神经精神疾病和传染病。。

In tandem with the fundraise, Stellaromics has appointed Todd Dickinson, Ph.D., as President & CEO. Dickinson is a life sciences industry pioneer, with more than 20 years of experience developing and commercializing disruptive genomics technologies. He was an early scientist of Illumina, and held a variety of technical and commercial executive roles both at Illumina, Bionano Genomics, and most recently as CEO of Cantata Bio (formerly Dovetail Genomics and Arc Bio)..

在筹集资金的同时，Stellaromics任命Todd Dickinson博士为总裁兼首席执行官。Dickinson是生命科学行业的先驱，拥有20多年开发和商业化颠覆性基因组学技术的经验。他是Illumina的早期科学家，在Illumina，Bionano Genomics以及最近担任Cantata Bio（以前称为Dovetail Genomics和Arc Bio）首席执行官的各种技术和商业执行职位。。

In addition, Ye Fu, Ph.D., has been appointed as CTO. Fu most recently served as Principal at Plaisance Capital Management, where he was a founding team member at several breakthrough biotech companies and a co-founder of Stellaromics. He is widely published, including first author articles in Cell and Nature Chemical Biology, with more than 18,000 citations.

此外，叶福博士已被任命为首席技术官。傅最近担任Plaisance资本管理公司的首席执行官，他是几家突破性生物技术公司的创始团队成员，也是Stellaromics的联合创始人。他被广泛发表，包括Cell and Nature Chemical Biology的第一作者文章，被引用超过18000次。

His PhD thesis opened the field of reversible RNA modifications, which is the foundational work for the 2023 Wolf Prize in Chemistry, one of the most prestigious international chemistry awards..

他的博士论文开辟了可逆RNA修饰领域，这是2023年沃尔夫化学奖的基础工作，该奖是最着名的国际化学奖之一。。

Founding Team Defining the Next Generation of Spatial TechnologyStellaromics Scientific Co-Founders are world-renowned scientists Karl Deisseroth, M.D., Ph.D., and Xiao Wang, Ph.D. Together, they patented the company's proprietary technology, STARmap (Spatially-resolved Transcript Amplicon Readout mapping), capable of measuring expression levels of thousands of genes within intact tissue, at the sub-cellular, single molecule level.

定义下一代空间技术的创始团队Tellaromics Scientific联合创始人是世界知名科学家Karl Deisseroth，M.D.，Ph.D。和Xiao Wang，Ph.D。他们共同为该公司的专有技术STARmap（空间分辨转录扩增子读数映射）申请专利，能够测量完整组织内数千个基因的表达水平，在亚细胞，单分子水平。

Most recently, Wang has developed a breakthrough RIBOmap (ribosome-bound mRNA mapping) technology to measure protein synthesis at single-cell and spatial resolution. Stellaromics technology is based on their ground-breaking research and innovations, as published in Science, Nature, and Cell..

最近，Wang开发了一种突破性的RIBOmap（核糖体结合mRNA作图）技术，用于测量单细胞和空间分辨率下的蛋白质合成。Stellaromics技术基于科学，自然和细胞杂志上发表的突破性研究和创新。。

'Stellaromics is on a mission to propel biomedical research forward by setting a new standard in in situ spatial analysis. Spatial biology has quickly established itself as one of the most exciting biological technologies of this decade. But today's approaches remain constrained to two-dimensional tissue profiles, and limited largely to expression of a handful of genes at a single point in time.  Our goal is to enable scientists to capture ultra high-resolution, three-dimensional, multi-omic information from thick tissue samples, mapping not only gene expression patterns, but also revealing those genes that are being translated to proteins.

“Stellaromics的使命是通过制定新的原位空间分析标准来推动生物医学研究的发展。空间生物学很快成为本十年来最激动人心的生物技术之一。但是今天的方法仍然局限于二维组织谱，并且主要限于在单个时间点表达少数基因。我们的目标是使科学家能够从厚组织样本中捕获超高分辨率，三维，多组学信息，不仅可以绘制基因表达模式，还可以揭示那些正在转化为蛋白质的基因。

By generating a far richer, functional readout of each cell in its native state across a broad range of different samples, from tumors to neurological disease samples, our technology will enable a new level of insight into the mechanisms of disease and how to treat them,' said CEO Dickinson. 'With this round of funding, we are entering an exciting growth phase as we expand our team, invest in both innovation and product development, and begin commercialization of what we believe will be a transformative in situ 3D profiling technology.'.

通过在从肿瘤到神经系统疾病样本的各种不同样本中产生更丰富，功能更丰富的天然状态的每个细胞读数，我们的技术将使人们对疾病机制以及如何治疗疾病有一个新的层次。'首席执行官迪金森说。'通过这轮资金，我们正在进入一个令人兴奋的增长阶段，因为我们扩大了团队，投资于创新和产品开发，并开始商业化我们认为将是一种变革性的原位3D分析技术。

With a clear vision to simplify and automate the process of capturing high resolution 3D information inside in situ tissue, this latest round of financing will be used to fortify the business and establish a new company headquarters to house its growing team of innovators. The company will continue to focus on advancing the development of its revolutionary Plexa™ products; the alpha version is expected to be available via a Technology Access Program in early 2024.

凭借简化和自动化在原位组织内捕获高分辨率3D信息过程的明确愿景，最新一轮融资将用于加强业务并建立新的公司总部，以容纳不断增长的创新者团队。公司将继续致力于推进革命性神经丛的发展™ 产品；预计alpha版本将于2024年初通过技术访问计划提供。

.

.

About Stellaromics

关于Stellaromics

Stellaromics, founded in 2022 and based in Boston, is advancing biomedical research with patented technology that deciphers intricate 3D transcription and translation patterns in native biological tissue. Their flagship product, STARmap (Spatially-resolved Transcript Amplicon Readout mapping), reveals gene expression patterns within intact tissue, aiding in the identification of treatment targets and supporting biomedical research.

Stellaromics成立于2022年，总部设在波士顿，采用专利技术推进生物医学研究，破译天然生物组织中复杂的3D转录和翻译模式。他们的旗舰产品STARmap（空间分辨转录扩增子读数映射）揭示了完整组织内的基因表达模式，有助于确定治疗目标并支持生物医学研究。

Stellaromics is in late-stage product development on its Plexa™ suite of products, designed to enable researchers and clinicians to create detailed cellular maps for enhanced disease understanding. For more information, visit stellaromics.com..

Stellaromics正处于产品开发的后期阶段™ 一套产品，旨在使研究人员和临床医生能够创建详细的细胞图，以增强对疾病的理解。欲了解更多信息，请访问stellaromics.com。。

Media inquiries:stellaromics@oakstreetcommunications.com

媒体查询：stellaromics@oakstreetcommunications.com

SOURCE Stellaromics

源Stellaromics